However, the complexity of metabolic programs in cancer cells and the potential for adaptive resistance require the development of combination therapies that target MYC-driven metabolism alongside other cellular pathways such as compensatory signaling pathways and DNA repair. This evidence concerns the gene MYC and cancer.